Brief: Surface Oncology To Collaborate With Roche On Immuno-Oncology Study Evaluating SRF388
04/06/2021 12:13
June 4 (Reuters) - Surface Oncology Inc SURF.O :
* SURFACE ONCOLOGY TO COLLABORATE WITH ROCHE ON
IMMUNO-ONCOLOGY
STUDY EVALUATING SRF388, TARGETING IL-27, AS PART OF A NOVEL
COMBINATION IN PATIENTS WITH ADVANCED TREATMENT-NAÏVE
HEPATOCELLULAR CARCINOMA
Source text for Eikon: ID:nGNXmLTyR
Further company coverage: SURF.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Surface Oncology
See all newsBrief: Surface Oncology Says Anticipates Will Have Net Cash Of $20 Million To $25 Million At The Closing Of The Proposed Mergers
Surface Oncology Inc reports results for the quarter ended in June - Earnings Summary
Brief: Surface Oncology, Inc. Q2 Net Income USD -28.2 Mln
Surface Oncology Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: ADAR1 Partners Reports 5.24% Passive Stake In Surface Oncology Inc As Of July 10 - SEC Filing